A Multicenter, Open-label Single Arm Study to Evaluate the Safety and Efficacy of Sparsentan in Posttransplant Immunoglobulin A Nephropathy (IgAN) or Focal Segmental Glomerulosclerosis (FSGS) (SPARX)

To evaluate the safety and efficacy of sparsentan tablets for the treatment of patients with proteinuria after kidney transplantation with once-daily dosing for 36 weeks.

CT.gov Identifier

NCT07219121

EudraCT Identifier

N/A

CTIS:

N/A

Collaborator

N/A

Study Contact Information

+1 888 969 7879

Recruiting

Study Details

Diseases

IgA nephropathy

Focal Segmental Glomerulosclerosis

Study Drug

Sparsentan

Undisclosed - immunosuppressive drug

Genes

N/A

Study Dates

Oct 2025 - Mar 2027

Sex

Female & Male

Age

18+ years

Inclusion and Exclusion Criteria

Inclusion Criteria:

* Willing and capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.
* Male and female aged ≥18 years
* Participants with a kidney transplant with biopsy-proven IgAN or FSGS histological pattern in the graft.
* A period of ≥12 months since kidney transplantation.
* UPCR ≥0.5 g/g and eGFR (CKD-EPI creatinine-based formula ≥30 mL/min/1.73 m2.
* Participants who can become pregnant, must agree to the use of 1 highly reliable method of contraception from 7 days prior to the first dose of study intervention until 30 days after the last dose of study intervention.
* Systolic BP ≤160 mmHg and ≥100 mmHg, and diastolic BP ≤100 mmHg and ≥60 mmHg at screening.
* For participants on an ACEI and/or ARB, and/or sodium glucose cotransporter-2 (SGLT2) inhibitor, the dosing regimen(s) is stable for ≥6 weeks prior to screening.

Exclusion Criteria:

Participant has multiorgan transplants (with the exception of pancreas and corneal transplants).
* Immunosuppressive therapy (IST) regimen for kidney transplant or other systemic chronic ISTs including enteric budesonide that is not stable for >6 weeks prior to Day 1. Exceptions include routine changes in the dose of CNIs to meet target level.
* <3 months after antirejection treatment and active rejection.
* Active bacterial, fungal or viral infection and/or active treatment of infection including BK virus (BKV), cytomegalovirus (CMV), human immunodeficiency virus (HIV), Hepatitis B and C <3 months prior to and during the screening period.
* Current treatment for surgical complications.
* History of heart failure (New York Heart Association [NYHA] Class II-IV).
* Jaundice, hepatitis, or known hepatobiliary disease.
* Malignancy within the past 2 years with the exception of adequately treated basal cell carcinoma or non-metastatic squamous cell carcinoma of the skin, with no evidence or recurrence.
* History of alcohol or illicit drug use disorder (as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition).
* History of serious side effects or allergic response to any angiotensin II antagonist or ERA.
* Participant requires any of the prohibited concomitant medications.
* Treatment with sparsentan <12 weeks prior to screening.
* Participant has participated in a study of another investigational product <28 days prior to screening or plans to participate in such a study during the course of this study.
* Hematocrit <27%, hemoglobin <90 g/L (9 g/dL), or potassium >5.5 mmol/L (5.5 mEq/L).
* The participant is pregnant, plans to become pregnant during the course of the study, or is breastfeeding.
* The participant, in the opinion of the Investigator, is unable to adhere to the requirements of the study, including the ability to swallow the study IMP whole.
* The participant, in the opinion of the Investigator, has a medical condition or abnormal clinically significant laboratory screening value not listed above that may interfere with the evaluation of sparsentan safety or activity.

Protocol Summary

To evaluate the safety and efficacy of sparsentan tablets for the treatment of patients with proteinuria after kidney transplantation with once-daily dosing for 36 weeks.

Study Locations

To view all trial locations, click here

Contact Us About More Information for the Clinical Trial Concierge Service

Natera’s Clinical Trial Concierge Program is comprised of a dedicated team that helps connect providers and patients with appropriate clinical trials. To learn more about a trial offered through this service, please complete the form below.

Fields marked with asterisk (*) are mandatory.